Close

AIA Oath or Declaration: BIO Comments

Mar 7 2012

...

Spurring Job Growth Through Capital Formation While Protecting Investors

Mar 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country.

2013 Draft Call Letter: BIO's Comments to CMS

Mar 1 2012

...

Letter to the Texas Health and Human Services Commission Regarding Proposed Specialty Pharmacy Rule

Mar 1 2012
  Comments on a proposed Texas Administrative Code that would classify biologics as specialty drugs. 

Biologics: BIO Comments on EMA 'Concept Paper on the Revision of the Guideline on Similar Biological medicinal Product"

Feb 28 2012

...

Good Guidance Practices: FDA Report on Good Guidance Practices: Improving Efficiency and Transparency

Feb 28 2012

...

PCORI National Patient and Stakeholder Dialogue: BIO's Public Statement

Feb 26 2012

...

Safety Labeling: Establishing Timeframes for Implementation of Product Safety Labeling Changes

Feb 20 2012

...

USPTO Genetic Testing Study: BIO's Testimony

Feb 17 2012
If a poor patient in Nevada doesn’t have access to an advanced molecular diagnostic test, and right across the border in California a similar patient has access to the same test, there’s obviously something wrong with that, but how can that be a patent problem?

Sunshine: BIO submits comments to CMS on Physician Payment proposed rule

Feb 16 2012
...